CalciMedica to Review Phase 2b CARPO Trial Data of Auxora in Acute Pancreatitis

CalciMedica Inc. announced that it will hold a call on Wednesday, October 30, 2024, at 12 p.m. ET/ 9 a.m. PT to discuss the full data set and win ratio analysis from its Phase 2b CARPO trial of Auxora™ in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The announcement was made on October 28, 2024, from the company's headquarters in La Jolla, California.

The Phase 2b CARPO trial of Auxora™ is a key study for CalciMedica. It is a randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate the efficacy of Auxora in treating patients with AP and SIRS. Professor Robert Sutton from the University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, who also chairs the Steering Committee for the CARPO trial, will present the findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. His presentation, entitled "A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with AP and Accompanying SIRS - CARPO," will offer detailed insights into the trial outcomes.

CalciMedica is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for inflammatory and immunologic diseases by targeting calcium release-activated calcium (CRAC) channels. These channels play a crucial role in immune cell function, and their inhibition can help modulate immune responses and protect against tissue injury. The company's lead product candidate, Auxora™, has shown promising results in multiple clinical trials, including the CARPO trial for AP with SIRS and the CARDEA trial for patients with COVID pneumonia.

In addition to the CARPO and CARDEA trials, CalciMedica is conducting several other important clinical studies. These include the KOURAGE trial, a Phase 2 study in patients with acute kidney injury (AKI) and associated acute hypoxic respiratory failure (AHRF), and the CRSPA trial, a Phase 1/2 study in patients with acute interstitial pneumonitis (AIPT). The company aims to develop CRAC channel inhibition therapies to address life-threatening inflammatory and immunologic diseases for which no approved treatments currently exist.

CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research. The company is headquartered in La Jolla, California, and continues to advance its proprietary technology to provide therapeutic benefits in critical medical conditions.

During the conference call and webcast scheduled for October 30, 2024, stakeholders, including stockholders and other interested parties, will have the opportunity to access the live event. The webcast can be accessed through the "Upcoming Events" section of CalciMedica's investor relations website. An archived version of the webcast will be available following the event's conclusion. Participants can join the call by dialing specific numbers and following the operator's prompts to join the CalciMedica Phase 2b CARPO Full Data Set & Win Ratio call.

The announcement underscores CalciMedica's commitment to transparency and communication with its stakeholders, providing critical updates on its clinical trials and the progress of its innovative therapies. As the company continues to develop its CRAC channel inhibition technology, it remains focused on addressing unmet medical needs in the field of inflammatory and immunologic diseases.